We’re looking for 4-6 Insight volunteers to join our Welcome and Induction project group.

Are you already volunteering with us and have you already seen or used our welcome and induction checklists? If so, this is a great opportunity to help us improve this resource and the support we give to volunteers starting a new role. Apply here if you’re interested in joining this project group.

“I’m very excited to lead such a valued and respected charity at this crucial moment, and I’m keen to contribute my energies to making sure everyone affected by MS gets the best deal possible.”

Nick Moberly, speaking on his appointment.

We’re delighted to announce that Nick Moberly will be joining us as CEO in 2019. Nick joins us at a moment of great opportunity for people affected by MS, both in terms of the help we can provide, and our work to stop the progression of MS.

Back in June, we launched our biggest campaign on Personal Independence Payment (PIP) yet. We called on the UK Government to scrap the PIP 20 metre rule. Since then, thousands of people from across the MS community have joined the call.

We’ll be handing in the petition to the UK Government on Wednesday 17 October. If you haven’t already, please sign and share the petition. It will close on Sunday 14 October.

We’ve had the disappointing news that MS drug ocrelizumab won’t be made available for primary progressive MS. The National Institute of Health and Care Excellence (NICE), who approve drugs to be available on the NHS in England and Wales, announced their decision on 10 September.

What is ocrelizumab and why does this decision matter?

Ocrelizumab (brand name Ocrevus) is a drug that has a Europe-wide license to treat relapsing MS and early primary progressive MS. It’s taken as an infusion.

We’re upgrading MS Society email - find out why, how and when.